Lv21
190 积分 2023-07-16 加入
236-OR: Volagidemab, a Human Glucagon Receptor Antagonist, Improves Glycemic Control in Subjects with Type 1 Diabetes (T1D): A 12-Week, Randomized, Double-Blind, Placebo-Controlled Trial
7小时前
求助中
682-P: Novel Dual Glucagon and Glucagon-Like Peptide-1 Receptor Agonist LY3305677 Improves Glucose Control, Reduces Body Weight, and Increases Energy Expenditure in Mice
1个月前
已关闭
The Design and Optimization of Monomeric Multitarget Peptides for the Treatment of Multifactorial Diseases
1个月前
已完结
G protein-coupled receptor signaling: transducers and effectors
1个月前
已完结
Glucagon receptor antagonist volagidemab in type 1 diabetes: a 12-week, randomized, double-blind, phase 2 trial
2个月前
已完结
Continuously recording fluorescent assays optimized for five human matrix metalloproteinases
5个月前
已完结
25 years of anti-TNF treatment for inflammatory bowel disease: lessons from the past and a look to the future
5个月前
已完结
Fibroblasts in immune-mediated inflammatory diseases: The soil of inflammation
5个月前
已完结
The global burden of IBD: from 2015 to 2025
5个月前
已完结
Breaking the therapeutic ceiling in drug development in ulcerative colitis
6个月前
已完结
皖公网安备34019202002308
